

Mikko Niemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9359913/publications.pdf>

Version: 2024-02-01

152
papers

15,862
citations

22153
59
h-index

16650
123
g-index

154
all docs

154
docs citations

154
times ranked

10965
citing authors

#	ARTICLE	IF	CITATIONS
1	PharmVar GeneFocus: <i>SLCO1B1</i>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	4.7	18
2	Integrating data from multiple Finnish biobanks and national health-care registers for retrospective studies: Practical experiences. Scandinavian Journal of Public Health, 2022, 50, 482-489.	2.3	7
3	Pharmacogenomics of celiprolol – evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics. Clinical and Translational Science, 2022, 15, 409-421.	3.1	4
4	Mental health conditions and adherence to direct oral anticoagulants in patients with incident atrial fibrillation: A nationwide cohort study. General Hospital Psychiatry, 2022, 74, 88-93.	2.4	11
5	The Clinical Pharmacogenetics Implementation Consortium Guideline for <i>SLCO1B1</i>, <i>ABCG2</i>, and <i>CYP2C9</i> genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	4.7	120
6	Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder. Pharmacogenomics Journal, 2022, 22, 166-172.	2.0	6
7	Genomewide Association Study of Simvastatin Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2022, 112, 676-686.	4.7	14
8	Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. European Journal of Clinical Pharmacology, 2021, 77, 643-650.	1.9	11
9	Protein Phosphatase 1 Regulatory Subunit 3B Genotype at rs4240624 Has a Major Effect on Gallbladder Bile Composition. Hepatology Communications, 2021, 5, 244-257.	4.3	4
10	Identification of Glycochenodeoxycholate 3-O-β-Glucuronide and Glycodeoxycholate 3-O-β-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers. Clinical Pharmacology and Therapeutics, 2021, 109, 646-657.	4.7	30
11	Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients. EMBO Molecular Medicine, 2021, 13, e13492.	6.9	43
12	Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland. Clinical Epidemiology, 2021, Volume 13, 183-195.	3.0	9
13	Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins. Drug Metabolism and Disposition, 2021, 49, 658-667.	3.3	19
14	Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clinical Pharmacology and Therapeutics, 2021, 110, 768-776.	4.7	25
15	Comparative Hepatic and Intestinal Efflux Transport of Statins. Drug Metabolism and Disposition, 2021, 49, 750-759.	3.3	31
16	An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes – application to establishing CYP2C8 inhibitor selectivity. European Journal of Pharmaceutical Sciences, 2021, 162, 105810.	4.0	7
17	Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans. Clinical Pharmacology and Therapeutics, 2021, 110, 1622-1632.	4.7	20
18	Rifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers. Anesthesia and Analgesia, 2021, 133, 423-434.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Itraconazole Increases Ibrutinib Exposure 10-Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug–Drug Interaction. <i>Clinical and Translational Science</i> , 2020, 13, 345-351.	3.1	25
20	Placental transporter-mediated drug interactions and offspring congenital anomalies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 868-879.	2.4	9
21	Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. <i>Clinical and Translational Science</i> , 2020, 13, 1236-1243.	3.1	20
22	UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics—A Comprehensive Pharmacogenomic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 885-895.	4.7	11
23	Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-Lasting Inhibition of CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1254-1264.	4.7	13
24	CYP3A4 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 448-457.	4.7	22
25	CYP2D6 Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	13
26	Enantiospecific Pharmacogenomics of Fluvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 668-680.	4.7	26
27	Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1345-1361.	4.7	107
28	Warfarin dose requirement in patients having severe thrombosis or thrombophilia. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1684-1691.	2.4	10
29	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. <i>Drug Metabolism and Disposition</i> , 2019, 47, 377-385.	3.3	15
30	Response to the Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test? <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 322-322.	4.7	1
31	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 219-228.	4.7	51
32	Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1298-1308.	4.0	17
33	Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 749-756.	4.7	41
34	Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer—Which Factors Matter?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 653-662.	4.7	20
35	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. <i>Genetics in Medicine</i> , 2018, 20, 622-629.	2.4	66
36	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 341-345.	2.5	12

#	ARTICLE	IF	CITATIONS
37	Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 158-168.	4.7	19
38	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 495-504.	4.7	14
39	Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 481-488.	2.5	16
40	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions. <i>Drug Metabolism and Disposition</i> , 2018, 46, 141-150.	3.3	22
41	Reflux aspiration in lungs of dogs with respiratory disease and in healthy West Highland White Terriers. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 2074-2081.	1.6	20
42	Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials. <i>PLoS ONE</i> , 2018, 13, e0190272.	2.5	27
43	Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 38-45.	2.5	8
44	Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	37
45	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 83-95.	3.3	30
46	High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 291-296.	2.5	18
47	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1364-1371.	3.3	30
48	Postoperative oxycodone in breast cancer surgery: What factors associate with analgesic plasma concentrations?. <i>Scandinavian Journal of Pain</i> , 2016, 12, 118-119.	1.3	0
49	Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 674-684.	9.1	72
50	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. <i>Pharmacological Reviews</i> , 2016, 68, 168-241.	16.0	175
51	CML Patients with Primary Resistance or Suboptimal Response to TKI Therapy Have Variants in Genes Affecting Drug Absorption and Metabolism. <i>Blood</i> , 2016, 128, 3071-3071.	1.4	2
52	Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1131-1138.	2.4	35
53	Drug-Related Inadvertent Deaths in a University Hospital – A Declining Trend. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 421-426.	2.5	22
54	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 382-387.	1.5	122

#	ARTICLE	IF	CITATIONS
55	Effect of grapefruit juice on the bioactivation of prasugrel. British Journal of Clinical Pharmacology, 2015, 80, 139-145.	2.4	13
56	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clinical Pharmacology and Therapeutics, 2015, 97, 650-658.	4.7	70
57	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. Drug Metabolism and Disposition, 2015, 43, 1655-1660.	3.3	25
58	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. Clinical Pharmacology and Therapeutics, 2014, 96, 498-507.	4.7	124
59	Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. Drug Metabolism and Disposition, 2014, 42, 2068-2076.	3.3	9
60	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2014, 95, 307-313.	4.7	49
61	Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer. Pediatric Blood and Cancer, 2014, 61, 797-802.	1.5	24
62	Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Medicine, 2013, 5, 1.	8.2	198
63	Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology, 2013, 1, 6.	3.3	41
64	PharmGKB summary. Pharmacogenetics and Genomics, 2013, 23, 721-728.	1.5	36
65	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. British Journal of Clinical Pharmacology, 2013, 75, 1488-1496.	2.4	32
66	SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenetics and Genomics, 2013, 23, 19-24.	1.5	36
67	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences, 2012, 33, 312-322.	8.7	85
68	PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2012, 91, 1044-1052.	4.7	131
69	Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. Clinical Pharmacology and Therapeutics, 2012, 92, 68-71.	4.7	64
70	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. European Journal of Clinical Pharmacology, 2012, 68, 681-688.	1.9	13
71	Gender, but not CYP7A1 or SLCO1B1 Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 245-252.	2.5	37
72	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 2011, 63, 157-181.	16.0	546

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of Intravenous Paracetamol in Elderly Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 121-129.	3.5	63
74	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 359-367.	2.0	54
75	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 718-726.	2.4	80
76	Frequencies of Single-Nucleotide Polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 Genes in a Finnish Population. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 9-13.	2.5	28
77	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 579-586.	4.7	50
78	Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 181-186.	4.0	16
79	No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1159-1167.	1.9	6
80	Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1977-1986.	3.3	58
81	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 497-502.	1.9	24
82	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 865-870.	1.9	7
83	High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 51-60.	2.3	90
84	SLCO1B1 Polymorphism and Oral Antidiabetic Drugs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 775-781.	2.5	34
85	Transporter Pharmacogenetics and Statin Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 130-133.	4.7	299
86	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 223-230.	4.7	54
87	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.	46.4	2,886
88	Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR112 Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 581-597.	2.0	25
89	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 207-213.	2.4	52
90	ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 197-203.	4.7	365

#	ARTICLE	IF	CITATIONS
91	Impact of OATP transporters on pharmacokinetics. British Journal of Pharmacology, 2009, 158, 693-705.	5.4	783
92	Different effects of the <i>ABCG2</i> c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics, 2009, 10, 1617-1624.	1.3	171
93	CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. Drug Metabolism and Disposition, 2009, 37, 2359-2366.	3.3	49
94	Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenetics and Genomics, 2009, 19, 447-457.	1.5	56
95	Global analysis of genetic variation in <i>SLCO1B1</i> . Pharmacogenomics, 2008, 9, 19-33.	1.3	168
96	The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. Clinical Pharmacology and Therapeutics, 2008, 84, 403-411.	4.7	79
97	Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clinical Pharmacology and Therapeutics, 2008, 84, 488-496.	4.7	71
98	No significant effect of <i>SLCO1B1</i> polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology, 2008, 65, 78-86.	2.4	52
99	The effect of <i>SLCO1B1</i> polymorphism on repaglinide pharmacokinetics persists over a wide dose range. British Journal of Clinical Pharmacology, 2008, 66, 818-825.	2.4	62
100	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics, 2008, 47, 463-474.	3.5	177
101	Different Effects of <i>SLCO1B1</i> Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide. Journal of Clinical Pharmacology, 2008, 48, 311-321.	2.0	83
102	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics Journal, 2008, 8, 268-277.	2.0	59
103	Trimethoprim and the <i>CYP2C8</i> ^{*3} Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. Drug Metabolism and Disposition, 2008, 36, 73-80.	3.3	110
104	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenetics and Genomics, 2008, 18, 77-90.	1.5	71
105	Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and Genomics, 2008, 18, 921-926.	1.5	29
106	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and Genomics, 2008, 18, 937-942.	1.5	59
107	Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 2007, 8, 787-802.	1.3	241
108	Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin. Clinical Pharmacology and Therapeutics, 2007, 82, 726-733.	4.7	381

#	ARTICLE	IF	CITATIONS
109	Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. British Journal of Clinical Pharmacology, 2007, 63, 732-740.	2.4	66
110	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. European Journal of Clinical Pharmacology, 2007, 63, 463-469.	1.9	34
111	Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans. Pharmaceutical Research, 2007, 24, 239-247.	3.5	117
112	Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenetics and Genomics, 2006, 16, 565-568.	1.5	40
113	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and Genomics, 2006, 16, 801-808.	1.5	96
114	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics, 2006, 16, 873-879.	1.5	425
115	Muscle Symptoms Associated with Statins: A Series of Twenty Patients. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 51-54.	2.5	30
116	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British Journal of Clinical Pharmacology, 2006, 61, 706-715.	2.4	51
117	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clinical Pharmacology and Therapeutics, 2006, 79, 231-242.	4.7	44
118	Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical Pharmacology and Therapeutics, 2006, 79, 419-426.	4.7	96
119	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical Pharmacology and Therapeutics, 2006, 80, 356-366.	4.7	215
120	Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics, 2006, 80, 565-581.	4.7	705
121	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. European Journal of Clinical Pharmacology, 2006, 62, 409-415.	1.9	106
122	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. European Journal of Clinical Pharmacology, 2006, 62, 463-472.	1.9	79
123	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. European Journal of Clinical Pharmacology, 2006, 62, 503-509.	1.9	30
124	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics, 2005, 15, 303-309.	1.5	112
125	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics, 2005, 77, 468-478.	4.7	320
126	Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2005, 78, 388-399.	4.7	180

#	ARTICLE	IF	CITATIONS
127	Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding) Tj ETQq1 1 0,784314 rgBT /Overl	2.4	134
128	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. British Journal of Clinical Pharmacology, 2005, 60, 208-217.	2.4	36
129	CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients. Molecular Diagnosis and Therapy, 2005, 5, 191-195.	3.3	36
130	Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundamental and Clinical Pharmacology, 2004, 18, 621-626.	1.9	108
131	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 124-30.	3.0	29
132	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. British Journal of Clinical Pharmacology, 2004, 57, 441-447.	2.4	81
133	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics, 2004, 76, 239-249.	4.7	80
134	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
135	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics and Genomics, 2004, 14, 523-525.	5.7	173
136	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46, 347-351.	6.3	269
137	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, 46, 1319-1323.	6.3	167
138	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 25-31.	4.7	20
139	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 380-387.	4.7	154
140	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. British Journal of Clinical Pharmacology, 2003, 56, 427-432.	2.4	40
141	Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics, 2003, 42, 819-850.	3.5	591
142	Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clinical Pharmacology and Therapeutics, 2002, 72, 362-369.	4.7	62
143	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes*. Clinical Pharmacology and Therapeutics, 2002, 72, 326-332.	4.7	172
144	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology and Therapeutics, 2001, 70, 484-492.	4.7	18

#	ARTICLE	IF	CITATIONS
145	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 194-200.	4.7	59
146	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 400-406.	4.7	104
147	The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 58-65.	4.7	88
148	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 591-595.	2.4	46
149	Rifampin decreases the plasma concentrations and effects of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 495-500.	4.7	91
150	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. <i>European Journal of Clinical Pharmacology</i> , 2000, 56, 225-229.	1.9	111
151	ENZYME HISTOCHEMISTRY OF THE ANGLE OF THE ANTERIOR CHAMBER OF THE HUMAN EYE. <i>Acta Ophthalmologica</i> , 1967, 45, 93-99.	1.1	8
152	APPLICATION OF ENZYME HISTOCHEMICAL METHODS IN THE DIFFERENTIAL DIAGNOSIS OF MELANOMA AND LEIOMYOMA OF THE IRIS. <i>Acta Pathologica Et Microbiologica Scandinavica</i> , 1967, 70, 53-57.	0.0	2